- Asia
- Automobile
- Bangladesh
- Banking
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Media
- Digital Right Management
- Educational Conferences/ Seminar
- Fashion Law
- GDPR
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Khadi Industries
- labour Law
- Legal Issues
- Licensing
- Media & Entertainment Law
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Online Gaming
- Patent Act
- Patent Commercialisation
- Patent Fess
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Protection of SMEs
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stock Exchange
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
Sun Pharmaceuticals v. Eli Lilly: Doctrine of Obviousness-Type Double Patenting
16th December, 2010 - 8:38 am
Categories:
Patent Litigation
Pharma/Biotech Patent Litigations
0 Comments
A remarkable latest change in the Patentability has risen from the decision of the Federal Circuit in the case Sun Pharmaceuticals v. Eli Lilly, over the later’s patent that claimed the use of gemcitabine (GEMZAR), a drug to treat cancer. Sun Pharma moved to lower court to invalidate this patent on the grounds of obviousness-type … Continue reading Sun Pharmaceuticals v. Eli Lilly: Doctrine of Obviousness-Type Double Patenting
Read more »EMERGING IP LANDSCAPE FOR GENERIC PHARMA COMPANIES: A CASE STUDY
IP Issues that concern generic pharma companies generally center on ANDA filing, Patent Litigation, Patent Outlicensing and Brand Acquisitions. It has been very rare for an Indian generic player to be involved into all the four aspects in a single case involving a common drug molecule. One such case with India headquartered Sun Pharma as … Continue reading EMERGING IP LANDSCAPE FOR GENERIC PHARMA COMPANIES: A CASE STUDY
Read more »Eli Lilly Vs Sun Pharma and others
9th April, 2010 - 9:56 am
Categories:
Patent Litigation
Pharma/Biotech Patent Litigations
0 Comments
Lilly’s Patent relates to method of treating Attention-Deficit/ Hyperactivity disorder (ADHD) with administration of effective amount of Tomoxetine. Lilly markets atomoxetine capsule under the brand name STRATTERA®. The US Patent 5,658,590 was assigned to Lilly On August 19, 1997 with a principal claim that recites a particular method of treating ADHD. Submission of an Abbreviated … Continue reading Eli Lilly Vs Sun Pharma and others
Read more »